Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon α in progressive metastatic melanoma and renal cell carcinoma. Clin. Cancer Res., 6: 1267-1272, 2000. [2] (multiple letters)

Frederick J Meyers, G. C. De Gast

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon α in progressive metastatic melanoma and renal cell carcinoma. Clin. Cancer Res., 6: 1267-1272, 2000. [2] (multiple letters)'. Together they form a unique fingerprint.